Loading...
Evidence of clinical efficacy of a first generation CD19 CAR T cell in B cell malignancies
Shohdy, Kyrillus S Pillai, Manon Guest, Ryan D Rothwell, Dominic G Kirillova, Natalia Chow, Shien Gilham, David E Hawkins, Robert E
Shohdy, Kyrillus S
Pillai, Manon
Guest, Ryan D
Rothwell, Dominic G
Kirillova, Natalia
Chow, Shien
Gilham, David E
Hawkins, Robert E
Citations
Altmetric:
Abstract
The persistence and reactivity of CAR T cells were enhanced by adding co-stimulatory domains, which is the basis of currently approved CAR-T cell therapies. However, this comes at the expense of increasing toxicities from the strong cytokine release effect. This is the first report from anti-CD19 CAR-T cell therapy with a single activation domain to show a favourable safety profile and clinical efficacy with two patients who achieved durable responses up to 28 months in a cohort with heavily pretreated B cell malignancies.
Description
Date
2023
Publisher
Collections
Files
Keywords
Type
Article
Citation
Shohdy KS, Pillai M, Guest R, Rothwell D, Kirillova N, Chow S, et al. Evidence of clinical efficacy of a first generation CD19 CAR T cell in B cell malignancies. EJHaem. 2023 Aug;4(3):882-5. PubMed PMID: 37601889. Pubmed Central PMCID: PMC10435680. Epub 2023/08/21. eng.